Management of Chemotherapy-Induced Nausea and Vomiting (CINV): A Short Review on the Role of Netupitant-Palonosetron (NEPA)
(Source: Core Evidence)
Source: Core Evidence - July 26, 2020 Category: Drugs & Pharmacology Tags: Core Evidence Source Type: research

Vedolizumab in the Treatment of Ulcerative Colitis: An Evidence-Based Review of Safety, Efficacy, and Place of Therapy
(Source: Core Evidence)
Source: Core Evidence - April 1, 2020 Category: Drugs & Pharmacology Tags: Core Evidence Source Type: research

Apixaban: An Update of the Evidence for Its Place in the Prevention of Stroke in Patients with Atrial Fibrillation
(Source: Core Evidence)
Source: Core Evidence - January 20, 2020 Category: Drugs & Pharmacology Tags: Core Evidence Source Type: research

Pertuzumab in the treatment of HER2-positive breast cancer: an evidence-based review of its safety, efficacy, and place in therapy
(Source: Core Evidence)
Source: Core Evidence - October 31, 2019 Category: Drugs & Pharmacology Tags: Core Evidence Source Type: research

Anabolics in the management of glucocorticoid-induced osteoporosis: an evidence-based review of long-term safety, efficacy and place in therapy
(Source: Core Evidence)
Source: Core Evidence - August 23, 2019 Category: Drugs & Pharmacology Tags: Core Evidence Source Type: research

Tedizolid phosphate for the treatment of acute bacterial skin and skin-structure infections: an evidence-based review of its place in therapy
(Source: Core Evidence)
Source: Core Evidence - July 5, 2019 Category: Drugs & Pharmacology Tags: Core Evidence Source Type: research

Lomitapide: a review of its clinical use, efficacy, and tolerability
(Source: Core Evidence)
Source: Core Evidence - June 30, 2019 Category: Drugs & Pharmacology Tags: Core Evidence Source Type: research

Enasidenib in the treatment of relapsed/refractory acute myeloid leukemia: an evidence-based review of its place in therapy
(Source: Core Evidence)
Source: Core Evidence - April 26, 2019 Category: Drugs & Pharmacology Tags: Core Evidence Source Type: research

Clinical utility of patiromer, sodium zirconium cyclosilicate, and sodium polystyrene sulfonate for the treatment of hyperkalemia: an evidence-based review [Erratum]
(Source: Core Evidence)
Source: Core Evidence - February 27, 2019 Category: Drugs & Pharmacology Tags: Core Evidence Source Type: research

Eslicarbazepine acetate in the treatment of adults with partial-onset epilepsy: an evidence-based review of efficacy, safety and place in therapy
(Source: Core Evidence)
Source: Core Evidence - March 8, 2018 Category: Drugs & Pharmacology Tags: Core Evidence Source Type: research

Dupilumab: an evidence-based review of its potential in the treatment of atopic dermatitis
(Source: Core Evidence)
Source: Core Evidence - February 23, 2018 Category: Drugs & Pharmacology Tags: Core Evidence Source Type: research

Vinflunine for the treatment of advanced or metastatic transitional cell carcinoma of the urothelial tract: an evidence-based review of safety, efficacy, and place in therapy
(Source: Core Evidence)
Source: Core Evidence - January 24, 2018 Category: Drugs & Pharmacology Tags: Core Evidence Source Type: research

Clinical utility of patiromer, sodium zirconium cyclosilicate, and sodium polystyrene sulfonate for the treatment of hyperkalemia: an evidence-based review
(Source: Core Evidence)
Source: Core Evidence - March 23, 2017 Category: Drugs & Pharmacology Tags: Core Evidence Source Type: research

Canagliflozin in the treatment of type 2 diabetes: an evidence-based review of its place in therapy
(Source: Core Evidence)
Source: Core Evidence - March 14, 2017 Category: Drugs & Pharmacology Tags: Core Evidence Source Type: research

Iloperidone in the treatment of schizophrenia: an evidence-based review of its place in therapy
(Source: Core Evidence)
Source: Core Evidence - December 13, 2016 Category: Drugs & Pharmacology Tags: Core Evidence Source Type: research

Imiglucerase in the management of Gaucher disease type 1: an evidence-based review of its place in therapy
(Source: Core Evidence)
Source: Core Evidence - October 14, 2016 Category: Drugs & Pharmacology Tags: Core Evidence Source Type: research

Everolimus in the management of metastatic renal cell carcinoma: an evidence-based review of its place in therapy
(Source: Core Evidence)
Source: Core Evidence - September 1, 2016 Category: Drugs & Pharmacology Tags: Core Evidence Source Type: research

Pirfenidone in the treatment of idiopathic pulmonary fibrosis: an evidence-based review of its place in therapy
(Source: Core Evidence)
Source: Core Evidence - July 1, 2016 Category: Drugs & Pharmacology Tags: Core Evidence Source Type: research

Azilsartan medoxomil in the management of hypertension: an evidence-based review of its place in therapy
Conclusion: Azilsartan is a safe and effective treatment option for every stage of hypertension, both alone or in fixed-dose combination tablets with chlorthalidone or amlodipine. Beneficial effects of AZI were also noted in patients with any degree of renal impairment. In addition, safety profiles of AZI were similar to that of the placebo. Keywords: hypertension, pharmacology, azilsartan, blood pressure, pharmacokinetics, cost-effectiveness (Source: Core Evidence)
Source: Core Evidence - April 5, 2016 Category: Drugs & Pharmacology Tags: Core Evidence Source Type: research

Azilsartan medoxomil in the management of hypertension
Angeloni E (Source: Core Evidence)
Source: Core Evidence - April 5, 2016 Category: Drugs & Pharmacology Source Type: research

Clinical utility of tadalafil in the treatment of pulmonary arterial hypertension: an evidence-based review
Adam M Henrie, James J Nawarskas, Joe R Anderson College of Pharmacy, University of New Mexico, Albuquerque, NM, USA Abstract: Pulmonary arterial hypertension (PAH) is a chronic and disabling condition characterized by an elevated pulmonary vascular resistance and an elevated mean pulmonary arterial pressure. Despite recent improvements in treatment availability, PAH remains challenging to treat, burdensome for patients, and ultimately incurable. Tadalafil is a phosphodiesterase-5 inhibitor that is administered once daily by mouth for the treatment of PAH. Current treatment guidelines recommend tadalafil as an option for p...
Source: Core Evidence - November 1, 2015 Category: Drugs & Pharmacology Tags: Core Evidence Source Type: research

Tadalafil in pulmonary arterial hypertension
Henrie AM, Nawarskas JJ, Anderson JR (Source: Core Evidence)
Source: Core Evidence - November 1, 2015 Category: Drugs & Pharmacology Source Type: research

Nintedanib: evidence for its therapeutic potential in idiopathic pulmonary fibrosis
Minoru Inomata,1 Yasuhiko Nishioka,2 Arata Azuma11Department of Pulmonary Medicine and Oncology, Graduate School of Medicine, Nippon Medical School, Sendagi, Bunkyo-ku, Tokyo, 2Department of Respiratory Medicine and Rheumatology, Institute of Health Biosciences, The University of Tokushima Graduate School, Tokushima, JapanAbstract: Idiopathic pulmonary fibrosis (IPF) is a progressive disease with poor prognosis. The molecular mechanisms involved in the progression of IPF are not fully understood; however, the platelet-derived growth factor (PDGF)/PDGF receptor pathway is thought to play a critical role in fibrogenesis of t...
Source: Core Evidence - August 27, 2015 Category: Drugs & Pharmacology Tags: Core Evidence Source Type: research

Effect of nintedanib in idiopathic pulmonary fibrosis
Inomata M, Nishioka Y, Azuma A (Source: Core Evidence)
Source: Core Evidence - August 26, 2015 Category: Drugs & Pharmacology Source Type: research

Palonosetron in the prevention of chemotherapy-induced nausea and vomiting: an evidence-based review of safety, efficacy, and place in therapy
Luigi Celio, Monica Niger, Francesca Ricchini, Francesco Agustoni Medical Oncology Unit 1, Department of Medical Oncology, Fondazione IRCCS Istituto Nazionale Tumori, Milan, Italy Introduction: The second-generation 5-hydroxytryptamine-3 (5-HT3) receptor antagonist palonosetron is effective in the prevention of chemotherapy-induced nausea and vomiting (CINV) associated with highly and moderately emetogenic chemotherapy (HEC and MEC, respectively). In addition, palonosetron has been the first and, at present, the only 5-HT3 receptor antagonist to have a specific indication for the prevention of delayed CINV associated with ...
Source: Core Evidence - August 21, 2015 Category: Drugs & Pharmacology Tags: Core Evidence Source Type: research

Review of palonosetron for CINV control
Celio L, Niger M, Ricchini F, Agustoni F (Source: Core Evidence)
Source: Core Evidence - August 20, 2015 Category: Drugs & Pharmacology Source Type: research

An evidence-based review of edoxaban and its role in stroke prevention in patients with nonvalvular atrial fibrillation
Tushar Acharya, Prakash Deedwania Division of Cardiology, Department of Internal Medicine, University of California, San Francisco, Fresno, CA, USA Abstract: Atrial fibrillation is the most common arrhythmia in the elderly. It is responsible for significant morbidity and mortality from cardioembolic complications like stroke. As a result, atrial fibrillation patients are risk-stratified using the CHADS2 or CHA2DS2-VASc scoring systems. Those at intermediate-to-high risk have traditionally been treated with therapeutic anticoagulation with warfarin for stroke prevention. Although effective, warfarin use is fraught with mult...
Source: Core Evidence - April 28, 2015 Category: Drugs & Pharmacology Tags: Core Evidence Source Type: research

Edoxaban for stroke prevention in atrial fibrillation
Acharya T, Deedwania P (Source: Core Evidence)
Source: Core Evidence - April 28, 2015 Category: Drugs & Pharmacology Source Type: research

Vilazodone for the treatment of major depressive disorder: an evidence-based review of its place in therapy
David J Hellerstein,1,2 Joseph Flaxer11Department of Psychiatry, Columbia University, 2New York State Psychiatric Institute, New York, NY, USAIntroduction: It has clearly been demonstrated that depressive disorders constitute a major worldwide public health problem, with massive economic and quality-of-life consequences. Existing pharmacological treatments have limited efficacy, with only about a third of patients achieving remission on any one medication. Delayed onset of action and variable tolerability contribute to this limited efficacy. Vilazodone, introduced in the US in 2011, has been described as the first member o...
Source: Core Evidence - April 20, 2015 Category: Drugs & Pharmacology Tags: Core Evidence Source Type: research

Vilazodone in depression
Hellerstein DJ, Flaxer J (Source: Core Evidence)
Source: Core Evidence - April 20, 2015 Category: Drugs & Pharmacology Source Type: research

Oritavancin for the treatment of acute bacterial skin and skin structure infections: an evidence-based review
Joumana Kmeid, Zeina A Kanafani Division of Infectious Diseases, Department of Internal Medicine, American University of Beirut Medical Center, Beirut, Lebanon Abstract: The emergence of resistance to glycopeptide antibiotics such as vancomycin and teicoplanin among Gram-positive bacteria has spurred the search for second-generation drugs of this class. Oritavancin, a promising novel, second-generation, semisynthetic lipoglycopeptide, is distinguished by two mechanisms of action: inhibition of cell wall synthesis and disruption of the cell membrane. This dual mechanism of action has increased the activity of oritavancin ag...
Source: Core Evidence - February 11, 2015 Category: Drugs & Pharmacology Tags: Core Evidence Source Type: research

Oritavancin for acute bacterial skin and skin structure infections
Kmeid J, Kanafani ZA (Source: Core Evidence)
Source: Core Evidence - February 10, 2015 Category: Drugs & Pharmacology Source Type: research

Rasburicase in the management of tumor lysis: an evidence-based review of its place in therapy
Jennifer Dinnel,1 Bonny L Moore,1 Brent M Skiver,1 Prithviraj Bose1,2 1Department of Internal Medicine, Virginia Commonwealth University, 2VCU Massey Cancer Center, Richmond, VA, USA Abstract: Tumor lysis syndrome (TLS) is a potentially life-threatening complication of cancer therapy characterized by two or more of the following laboratory abnormalities: hyperuricemia, hyperkalemia, hypocalcemia, and hyperphosphatemia, with resultant end-organ damage, eg, renal failure, seizures, or cardiac arrhythmias. High-risk patients include those with highly proliferative cancers and/or large tumor burdens, particularly in the settin...
Source: Core Evidence - January 12, 2015 Category: Drugs & Pharmacology Tags: Core Evidence Source Type: research

Rasburicase in the management of tumor lysis
Dinnel J, Moore BL, Skiver BM, Bose P (Source: Core Evidence)
Source: Core Evidence - January 12, 2015 Category: Drugs & Pharmacology Source Type: research

Dulaglutide: an evidence-based review of its potential in the treatment of type 2 diabetes
Conclusion: Dulaglutide is a once-weekly GLP-1 RA approved for the treatment of T2DM that has shown similar efficacy to other agents in this class. Keywords: GLP-1 RA, glucagon-like peptide-1 receptor agonist, incretin mimetic, type 2 diabetes mellitus therapy (Source: Core Evidence)
Source: Core Evidence - January 9, 2015 Category: Drugs & Pharmacology Tags: Core Evidence Source Type: research

Dulaglutide use in type 2 diabetes mellitus
Edwards KL, Minze MG (Source: Core Evidence)
Source: Core Evidence - January 8, 2015 Category: Drugs & Pharmacology Source Type: research

Sipuleucel-T in the treatment of prostate cancer: an evidence-based review of its place in therapy
Julie N Graff,1,2 Erin D Chamberlain31Portland VA Medical Center, 2Knight Cancer Institute, 3Department of Medicine, Oregon Health and Science University, Portland, OR, USAAbstract: Metastatic castration-resistant prostate cancer is the lethal form of cancer of the prostate. Five new agents that prolong survival in this group have emerged in the past 5 years, and sipuleucel-T is among them. Sipuleucel-T is the only immunotherapy shown to improve survival in prostate cancer. It is currently indicated in asymptomatic or mildly symptomatic patients, as it has never shown a direct cancer effect. This paper describes the proces...
Source: Core Evidence - December 18, 2014 Category: Drugs & Pharmacology Tags: Core Evidence Source Type: research

Sipuleucel-T in prostate cancer
Graff JN, Chamberlain ED (Source: Core Evidence)
Source: Core Evidence - December 17, 2014 Category: Drugs & Pharmacology Source Type: research

Luliconazole for the treatment of fungal infections: an evidence-based review
Deepshikha Khanna, Subhash Bharti Department of Dermatology, Chacha Nehru Bal Chikitsalaya (Childrens Hospital), Delhi, India Abstract: Luliconazole is an imidazole antifungal agent with a unique structure, as the imidazole moiety is incorporated into the ketene dithioacetate structure. Luliconazole is the R-enantiomer, and has more potent antifungal activity than lanoconazole, which is a racemic mixture. In this review, we summarize the in vitro data, animal studies, and clinical trial data relating to the use of topical luliconazole. Preclinical studies have demonstrated excellent activity against dermatophytes. Further,...
Source: Core Evidence - September 24, 2014 Category: Drugs & Pharmacology Tags: Core Evidence Source Type: research

Luliconazole for treatment of fungal infections
Khanna D, Bharti S (Source: Core Evidence)
Source: Core Evidence - September 24, 2014 Category: Drugs & Pharmacology Source Type: research

Colistimethate sodium for the treatment of chronic pulmonary infection in cystic fibrosis: an evidence-based review of its place in therapy
This article reviews the available evidence to reflect on the place of colistimethate sodium in the therapy of chronic pulmonary infection in CF. Keywords: Pseudomonas aeruginosa, treatment, multiresistant strains, Gram-negative bacteria, colistin (Source: Core Evidence)
Source: Core Evidence - September 19, 2014 Category: Drugs & Pharmacology Tags: Core Evidence Source Type: research